- Home
- LPG vs MLYS Comparison
LPG vs MLYS Comparison
Compare LPG & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPG
- MLYS
- Stock Information
- Founded
- LPG 2013
- MLYS 2019
- Country
- LPG United States
- MLYS United States
- Employees
- LPG N/A
- MLYS N/A
- Industry
- LPG Marine Transportation
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- LPG Consumer Discretionary
- MLYS Health Care
- Exchange
- LPG Nasdaq
- MLYS Nasdaq
- Market Cap
- LPG 913.3M
- MLYS 1.0B
- IPO Year
- LPG 2014
- MLYS 2023
- Fundamental
- Price
- LPG $21.31
- MLYS $15.70
- Analyst Decision
- LPG Strong Buy
- MLYS Strong Buy
- Analyst Count
- LPG 1
- MLYS 3
- Target Price
- LPG $35.00
- MLYS $33.00
- AVG Volume (30 Days)
- LPG 736.3K
- MLYS 838.4K
- Earning Date
- LPG 05-22-2025
- MLYS 05-12-2025
- Dividend Yield
- LPG 14.98%
- MLYS N/A
- EPS Growth
- LPG N/A
- MLYS N/A
- EPS
- LPG 2.14
- MLYS N/A
- Revenue
- LPG $349,670,662.00
- MLYS N/A
- Revenue This Year
- LPG $4.69
- MLYS N/A
- Revenue Next Year
- LPG N/A
- MLYS N/A
- P/E Ratio
- LPG $9.98
- MLYS N/A
- Revenue Growth
- LPG N/A
- MLYS N/A
- 52 Week Low
- LPG $16.66
- MLYS $8.24
- 52 Week High
- LPG $51.13
- MLYS $18.38
- Technical
- Relative Strength Index (RSI)
- LPG 45.64
- MLYS 55.54
- Support Level
- LPG $21.03
- MLYS $14.75
- Resistance Level
- LPG $21.92
- MLYS $16.11
- Average True Range (ATR)
- LPG 0.86
- MLYS 0.92
- MACD
- LPG -0.22
- MLYS -0.07
- Stochastic Oscillator
- LPG 29.43
- MLYS 48.28
About LPG Dorian LPG Ltd.
Dorian LPG Ltd is an international liquefied petroleum gas shipping company focused on owning and operating gas carriers, or VLGCs. The company currently owns and operates around 22 modern VLGCs, including nineteen new fuel-efficient 84,000 cbm ECO-design VLGCs. Dorian LPG has offices in Connecticut, USA, London, United Kingdom, and Athens, Greece.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.